News
Lilly’s tirzepatide claims head-to-head trial win against injectable
Eli Lilly’s investigational treatment tirzepatide has demonstrated superior A1C and body weight reduction compared to injectable semaglutide in adults with type 2 diabetes.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Eli Lilly’s investigational treatment tirzepatide has demonstrated superior A1C and body weight reduction compared to injectable semaglutide in adults with type 2 diabetes.